- Home
- RXRX
as 11-21-2025 3:39pm EST
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 2.2B | IPO Year: | 2021 |
| Target Price: | $7.25 | AVG Volume (30 days): | 37.2M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.79 - $12.36 | Next Earning Date: | 11-05-2025 |
| Revenue: | $43,689,000 | Revenue Growth: | -32.98% |
| Revenue Growth (this year): | 24.17% | Revenue Growth (next year): | 20.96% |
Stock Insider Trading Activity of Recursion Pharmaceuticals Inc. (RXRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gibson Christopher | RXRX | Chief Executive Officer | Nov 19 '25 | Sell | $4.16 | 40,000 | $166,400.00 | 913,839 | |
| Gibson Christopher | RXRX | Chief Executive Officer | Nov 4 '25 | Sell | $5.21 | 40,000 | $208,400.00 | 913,839 | |
| Gibson Christopher | RXRX | Chief Executive Officer | Sep 10 '25 | Sell | $4.71 | 100,000 | $471,000.00 | 913,839 | |
| Gibson Christopher | RXRX | Chief Executive Officer | Aug 26 '25 | Sell | $4.84 | 100,000 | $484,000.00 | 913,839 |
Latest Recursion Pharmaceuticals Inc. News
RXRX Breaking Stock News: Dive into RXRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Is Recursion Pharmaceuticals Set for Further Gains After Recent 36% Share Price Surge?
Simply Wall St.
a month ago
Recursion Pharmaceuticals (RXRX) Is Up 6.0% After New AI Partnerships and Exscientia Acquisition Has the Bull Case Changed?
GlobeNewswire
a month ago
AI in Biotechnology Research Report 2025: An $11.4 Billion Market by 2030, Dominated by NVIDIA, Tempus AI, Recursion Pharmaceuticals, Schrodinger, and Sophia Genetics
Motley Fool
a month ago
3 Growth Stocks to Invest $1,000 in Right Now
Zacks
a month ago
Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights
Insider Monkey
a month ago
Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event
Just Food
2 months ago
Clarebout Potatoes’ staff strike over bonuses linked to JR Simplot takeover
Wealth Management
2 months ago
World Investment Advisors Appoints Former Lincoln Executive President
Compare RXRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RXRX Recursion Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.